Belzutifan Market Summary

Key Factors Driving Belzutifan Growth

1. Expansion into additional renal cell carcinoma settings is significantly enlarging the addressable market: Belzutifan is a first-in-class oral HIF-2α inhibitor that blocks HIF-2α–mediated transcription of genes involved in tumor growth and angiogenesis. Its original approval in advanced RCC has now been supplemented by important new indications. In June 2026, the FDA approved belzutifan + pembrolizumab for adjuvant treatment of adults with clear-cell RCC at intermediate-high or high risk of recurrence after nephrectomy/resection. In LITESPARK-022, involving 1,841 patients, the combination reduced the risk of recurrence or death by 28% (HR 0.72) versus pembrolizumab alone.

2. A new belzutifan + lenvatinib combination provides another major growth catalyst: In September 2026, FDA approved belzutifan + lenvatinib for adults with advanced RCC with a clear-cell component following PD-1/PD-L1 inhibitor treatment. In the Phase 3 LITESPARK-011 study of 747 randomized patients, the combination produced median PFS of 14.6 months versus 10.6 months with cabozantinib and an ORR of 53% versus 40%. The combination reduced the risk of progression or death by 26% (HR 0.74). This is particularly important because it creates a new post-immunotherapy treatment option and positions belzutifan in combination with an established VEGFR-targeted agent.

3. Strong commercial momentum is already visible in reported sales: WELIREG generated $716 million in 2025 sales, up 41% from $509 million in 2024. Merck attributed the growth primarily to higher U.S. demand and continued launch uptake in international markets. Quarterly momentum also remained strong: Q4 2025 sales reached $220 million, versus $160 million in Q4 2024, representing 37% growth. This provides a verified commercial base from which the 2026 label expansions can drive further growth.

4. VHL disease provides a differentiated rare-disease market with long-term treatment potential: Belzutifan was initially approved for adults with von Hippel-Lindau (VHL) disease-associated RCC, CNS hemangioblastomas and pancreatic neuroendocrine tumors when surgery is unsuitable. The VHL indication is particularly attractive because the drug directly targets the underlying HIF-2α biology associated with VHL pathway disruption. Merck reported European Commission conditional approval in February 2025 for VHL-associated tumors and Japanese approval in June 2025, expanding international access.

5. Expansion into pheochromocytoma and paraganglioma adds another orphan-oncology opportunity: In May 2025, the FDA expanded WELIREG to adults and pediatric patients 12 years and older with locally advanced, unresectable or metastatic pheochromocytoma and paraganglioma (PPGL). This was based on LITESPARK-015 and provides another indication in which HIF-2α biology is clinically relevant. Because PPGL is rare and difficult to treat in advanced settings, regulatory approval expands belzutifan's potential patient base while reinforcing its position as a multi-indication HIF-2α targeted therapy.

Belzutifan Recent Developments

In September 2026, Merck & Co, and Eisai announced that the US Food and Drug Administration (FDA) approved the dual oral regimen of WELIREG (belzutifan), MSD’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus LENVIMA (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor.

“Belzutifan Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Belzutifan for approved indication like Paraganglioma, Phaeochromocytoma, Renal cell carcinoma, and Von Hippel-Lindau disease; as well as potential indication like Neuroendocrine tumours, Solid tumours, Gastrointestinal stromal tumours, HER2 negative breast cancer, and Prostate cancer in the 7MM. A detailed picture of Belzutifan’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Belzutifan for approved and potential indications. The Belzutifan market report provides insights about Belzutifan’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Belzutifan performance, future market assessments inclusive of the Belzutifan market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Belzutifan sales forecasts, along with factors driving its market.

Belzutifan Drug Summary

Belzutifan is an orally administered, small-molecule inhibitor of hypoxia-inducible factor-2 alpha (HIF-2α) developed by Merck & Co. It binds selectively to HIF-2α and prevents its interaction with HIF-1β, thereby suppressing transcription of downstream genes involved in cellular proliferation, angiogenesis, erythropoietin production, and tumor growth; this mechanism is particularly relevant in tumors associated with impaired von Hippel-Lindau (VHL) protein function. Belzutifan is available as oral tablets and is generally administered once daily. Its approved uses include treatment of adults with VHL disease requiring therapy for associated renal cell carcinoma (RCC), central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors when immediate surgery is not required; treatment of advanced clear-cell RCC following a PD-1/PD-L1 inhibitor and a VEGF-TKI; and, following recent expansion of its label, treatment of adults and pediatric patients aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). In 2026, the FDA further approved belzutifan in combination with pembrolizumab for adjuvant treatment of adults with clear-cell RCC at intermediate-high or high risk of recurrence following nephrectomy, and in combination with lenvatinib for advanced RCC with a clear-cell component following PD-1/PD-L1 inhibitor therapy. Belzutifan therefore represents an important targeted therapy for cancers driven by dysregulated HIF-2α signaling, particularly VHL-associated tumors and clear-cell RCC. The report provides Belzutifan’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Belzutifan Market Report

The report provides insights into:

• A comprehensive product overview including the Belzutifan MoA, description, dosage and administration, research and development activities in approved indications like Paraganglioma, Phaeochromocytoma, Renal cell carcinoma, and Von Hippel-Lindau disease; as well as potential indication like Neuroendocrine tumours, Solid tumours, Gastrointestinal stromal tumours, HER2 negative breast cancer, and Prostate cancer.
• Elaborated details on Belzutifan regulatory milestones and other development activities have been provided in Belzutifan market report.
• The report also highlights Belzutifan‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Belzutifan market report also covers the patents information, generic entry and impact on cost cut.
• The Belzutifan market report contains current and forecasted Belzutifan sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Belzutifan market report also features the SWOT analysis with analyst views for Belzutifan in approved and potential indications.

Methodology

The Belzutifan market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Belzutifan Analytical Perspective by DelveInsight

• In-depth Belzutifan Market Assessment

This Belzutifan sales market forecast report provides a detailed market assessment of Belzutifan for approved indication like Paraganglioma, Phaeochromocytoma, Renal cell carcinoma, and Von Hippel-Lindau disease; as well as potential indication like Neuroendocrine tumours, Solid tumours, Gastrointestinal stromal tumours, HER2 negative breast cancer, and Prostate cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Belzutifan sales data uptil 2034.

• Belzutifan Clinical Assessment

The Belzutifan market report provides the clinical trials information of Belzutifan for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Belzutifan Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Belzutifan Market Potential & Revenue Forecast

• Projected market size for the Belzutifan and its key indications
• Estimated Belzutifan sales potential (Belzutifan peak sales forecasts)
• Belzutifan Pricing strategies and reimbursement landscape

Belzutifan Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Belzutifan Market positioning compared to existing treatments
• Belzutifan Strengths & weaknesses relative to competitors

Belzutifan Regulatory & Commercial Milestones

• Belzutifan Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Belzutifan Clinical Differentiation

• Belzutifan Efficacy & safety advantages over existing drugs
• Belzutifan Unique selling points

Belzutifan Market Report Highlights

• In the coming years, the Belzutifan market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Belzutifan companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Belzutifan’s dominance.
• Other emerging products for Paraganglioma, Phaeochromocytoma, Renal cell carcinoma, and Von Hippel-Lindau disease; as well as potential indication like Neuroendocrine tumours, Solid tumours, Gastrointestinal stromal tumours, HER2 negative breast cancer, and Prostate cancer are expected to give tough market competition to Belzutifan and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Belzutifan in approved and potential indications.
• Analyse Belzutifan cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Belzutifan sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Belzutifan in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Belzutifan? How strong is Belzutifan’s clinical and commercial performance?
• What is Belzutifan’s clinical trial status in each individual indications such as Paraganglioma, Phaeochromocytoma, Renal cell carcinoma, and Von Hippel-Lindau disease; as well as potential indication like Neuroendocrine tumours, Solid tumours, Gastrointestinal stromal tumours, HER2 negative breast cancer, and Prostate cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Belzutifan Manufacturers?
• What are the key designations that have been granted to Belzutifan for approved and potential indications? How are they going to impact Belzutifan’s penetration in various geographies?
• What is the current and forecasted Belzutifan market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Belzutifan in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Belzutifan for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Belzutifan? What is the duration of therapy and what are the geographical variations in cost per patient?